Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.85 |
| ▸ | SLC10A2 | Q12908 | 6/20 | 0.32 |
| ▸ | CTSD | P07339 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17772069 | 1.00 | NR1H4 (0.85) | NR1H4SLC10A2CTSDMEN1KMT2A | |
| SCHEMBL21968920 | 1.00 | NR1H4 (0.85) | NR1H4SLC10A2CTSDMEN1KMT2A | |
| SCHEMBL19046596 | 1.00 | NR1H4 (0.85) | NR1H4SLC10A2CTSDMEN1KMT2A | |
| SCHEMBL919688 | 0.96 | NR1H4 (0.92) | NR1H4SLC10A2KMT2A | |
| SCHEMBL2697206 | 0.96 | NR1H4 (0.92) | NR1H4SLC10A2KMT2A | |
| SCHEMBL17772071 | 0.96 | NR1H4 (0.92) | NR1H4SLC10A2KMT2A | |
| SCHEMBL19046549 | 0.95 | NR1H4 (0.93) | NR1H4SLC10A2CTSD | |
| SCHEMBL918882 | 0.95 | NR1H4 (0.93) | NR1H4SLC10A2CTSD | |
| SCHEMBL4566711 | 0.95 | NR1H4 (0.93) | NR1H4SLC10A2CTSD | |
| SCHEMBL25118211 | 0.95 | NR1H4 (0.85) | NR1H4SLC10A2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777864-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2021-02-17 | — | — | EP | claimed |
| EP-3400944-B1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2020-07-15 | — | — | EP | claimed |
| US-20200069715-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2020-03-05 | — | — | US | claimed |
| US-10555950-B2 | Bile acid recycling inhibitors for treatment of obesity and diabetes | SATIOGEN PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | claimed |
| EP-3400944-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2018-11-14 | — | — | EP | claimed |
| EP-3023102-B1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2018-06-27 | — | — | EP | claimed |
| EP-1427423-B9 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | claimed |
| US-20160193277-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2016-07-07 | — | — | US | claimed |
| US-20160194353-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2016-07-07 | — | — | US | claimed |
| EP-3023102-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2016-05-25 | — | — | EP | claimed |
| US-20050113362-A1 | Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | ASTRAZENECA AB R & D HEADQUARTERS - GLOBAL IINTELLECTUAL PROPERT (SE) | 2005-05-26 | — | — | US | claimed |
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | ALBIREO AB (SE) | 2005-02-17 | — | — | US | claimed |
| WO-2004089350-A1 | USE OF AN IBAT INHIBITOR FOR THE TREATMENT OF PROPHYLAXIS OF CONSTIPATION | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | WO | claimed |
| EP-1458677-A1 | 3-PHENYL-2-ARYLALKYLTHIOPROPIONIC ACID DERIVATIVES AS SELECTIVE AGONISTS OF PPAR-ALPHA | Astrazeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| EP-1458673-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) | Astrazeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| EP-1427423-A1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | claimed |
| WO-2004006899-A1 | COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | claimed |
| WO-2003051826-A1 | 3-PHENYL-2-ARYLALKYLTHIOPROPIONIC ACID DERIVATIVES AS SELECTIVE AGONISTS OF PPAR-ALPHA | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| WO-2003051821-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| WO-2003022286-A1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194353-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | NR1H4 46/4885SLC10A2 3/4885CTSD 2620/4885 |
| US-20160193277-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | NR1H4 46/4885SLC10A2 3/4885CTSD 2620/4885 |
| US-10555950-B2 | Bile acid recycling inhibitors for treatment of obesity and diabetes | SLC10A1, SLC10A2, ABCB11 | NR1H4 5/4885SLC10A2 2/4885CTSD 1112/4885 |
| US-20050113362-A1 | Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | PPARA, PPARD, PPARG | NR1H4 33/4885SLC10A2 434/4885CTSD 3213/4885 |
| US-20200069715-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | NR1H4 4/4885SLC10A2 2/4885CTSD 877/4885 |
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | SLC10A2, SLC10A1, ABCB11 | NR1H4 4/4885SLC10A2 1/4885CTSD 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.